Evolution of the Average Target: Alcon Inc.

Evolution of the Target Price: Alcon Inc.

Changes in Analyst Recommendations: Alcon Inc.

f7fcbbc4b540cc5d9663.U2lfYrm26qUYIYKHrzD-u36PRpU-IzDrQf2Hz6EnAaM.BTApG8Pg3spsZ9bhnXin3i_hAtRPbgKvDrbkuJIUdpAqXjsXyPLf6ypwsg~0e4b7a431d8083de89e1e49fba3a4eac
Mar. 19 AlphaValue/Baader Europe Upgrades Alcon to Add Rating, Lifts PT MT
Mar. 16 Bernstein: Risk in Alcon's Implantables Business 'Manageable,' Already Priced In MT
Mar. 10 Bernstein Says Alcon Top Pick in European Medtech Coverage, Notes 'Good Momentum' for Key Products into FY26 MT
Mar. 06 Berenberg Keeps Alcon at Buy Amid Signs of US Cataract Market Rebound MT
Mar. 04 Alcon Kept at Outperform as RBC Notes 'Positive Setup' Through FY26; Estimates Revised MT
Feb. 27 Equita SIM Upgrades Alcon to Buy, Raises PT MT
Feb. 26 Needham Raises Price Target on Alcon to $100 From $98, Keeps Buy Rating MT
Feb. 26 Wells Fargo Upgrades Alcon AG to Overweight From Equal Weight, Adjusts PT to $97 From $88 MT
Feb. 26 Alcon Estimates Tweaked as Bernstein Notes Potential Upside from End-market Recovery; Price Target Up MT
Feb. 25 Alcon: Markets forgive Q4 miss for a healthy 2026 outlook Alphavalue
Feb. 18 RBC Updates Alcon Estimates Ahead of FY25 Earnings; Outperform Rating Kept MT
Feb. 11 RBC Expects Alcon's Upcoming FY26 Guidance to Drive Share Price Volatility; Outperform Rating Kept MT
Jan. 26 Berenberg Keeps Alcon at Buy on Expected FY26 Product-supported Growth MT
Jan. 20 Deutsche Bank Upgrades Alcon to Buy Rating, Boosts PT MT
Jan. 07 Swiss stocks - Factors to watch on January 7 RE
Dec. 17 Bernstein Bullish on Alcon's FY26 Earnings Growth Momentum; Outperform Maintained MT
Dec. 16 ISS Advises Staar Surgical Shareholders to Vote for Alcon Takeover Bid in Updated Recommendation MT
Dec. 09 Swiss Market Index Retreats; Swiss Re Shares Down MT
Nov. 13 Alcon shares rebound after solid third quarter Alphavalue
Nov. 13 Needham Trims Price Target on Alcon to $98 From $101, Keeps Buy Rating MT
Nov. 13 RBC Slightly Lowers FY25 Estimates for Alcon After Q3 Update MT
Nov. 11 (ALC) Alcon Reaffirms Full Year 2025 Adjusted EPS Range $3.05-$3.15, vs. FactSet Est of $3.08 MT
Nov. 04 Alcon releases investor discussion materials of merger proposal for Staar stockholders RE
Nov. 04 Alcon releases investor discussion materials reinforcing certain value of merger proposal for Staar shareholders RE
25-10-16 Independent Poxy Advisory Firms Issues Recommendations to Shareholders of Broadwood Partners CI

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+22.67%
+40.87%
+29.98%
+3.08%
+47.69%
+19.37%
+43.43%
+29.26%
+19.25%
Average +28.40%
Weighted average by Cap. +34.00%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
81.98USD
Average target price
100.52USD
Spread / Average Target
+22.61%
High Price Target
118.26USD
Spread / Highest target
+44.25%
Low Price Target
74.72USD
Spread / Lowest Target
-8.86%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

AlphaValue/Baader Europe
Equita SIM
Needham & Co.
Wells Fargo Securities
alphavalue Abhishek Raval
Deutsche Bank Securities
Citigroup
Barclays
Kepler Cheuvreux
Deutsche Bank Research
Redburn Atlantic
Ameriprise Advisor Services
RBC Capital Markets
Berenberg Bank
UBS
Oppenheimer
Stifel Nicolaus
Baird
Argus
Mizuho Securities
KeyBanc Capital Markets
Bernstein
Morgan Stanley
Jefferies & Co.
BNP Paribas Exane
Nephron Research
Societe Generale
JPMorgan Chase
BTIG
Credit Suisse
BNP Paribas
DA Davidson
Stephens Inc.
Goldman Sachs
Exane BNP
Kepler Capital Markets
SVB Leerink
Davy
Octagon Capital
JPMORGAN James Gordon
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
81.98USD
Average target price
100.52USD
Spread / Average Target
+22.61%

Quarterly revenue - Rate of surprise